Last checked at 13 Mar 2023 07:00
LungLife AI, Inc. (the "Company" or "LungLife")
Statement re. Silicon Valley Bank
LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, is aware of media reports indicating the closure of Silicon Valley Bank ("SVB"). The Company does not hold any cash at SVB, nor does it have a banking relationship with SVB.
For further information please contact:
LungLife AI, Inc. | www.lunglifeai.com |
Paul Pagano, CEO | Via Walbrook PR |
David Anderson, CFO |
|
|
|
Investec Bank plc (Nominated Adviser & Broker) | Tel: +44 (0)20 7597 5970 |
Virginia Bull / Cameron MacRitchie / Lydia Zychowska | |
Walbrook PR Limited | Tel: +44 (0)20 7933 8780 or LungLifeAI@walbrookpr.com |
Stephanie Cuthbert / Alice Woodings / Phillip Marriage | Mob: 07980 541 893 / 07407 804 654 / 07867 984 082 |
About LungLife
LungLife AI is a developer of clinical diagnostic solutions designed to make a significant impact in the early detection of lung cancer, the deadliest cancer globally. Using a minimally invasive blood draw, the Company's LungLB® test is designed to deliver additional information to clinicians who are evaluating indeterminate lung nodules. For more information visit www.lunglifeai.com
Our Purpose is to be a driving force in the early detection to lung cancer. Our Vision is to invert the 20:80 ratio such that in years to come at least 80% of lung cancer is detected early.